≪英文≫

Impact of body mass index on the efficacy of immune combination therapy in metastatic renal cell carcinoma: a multicenter study in Japan.

Anami T, Motoshima T, Matsushita Y, Kojima T, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Kawasaki Y, Kato T, Tatarano S, Masui K, Nakamura E, Kaneko T, Miyake M, Kitamura H, Miyake H, Kamba T; Japan Urological Oncology Group.

Int J Clin Oncol. 2025 Aug 20. doi: 10.1007/s10147-025-02823-0. Online ahead of print. PMID: 40835772

 

The Clock and the Scalpel: Does delayed Robot-assisted radical prostatectomy affect pathological progression and upgrading in prostate cancer?

Koterazawa S, Goto T, Kubota M, Mizuno K, Sumiyoshi T, Takaoka N, Shibasaki N, Shimizu Y, Kanno T, Soda T, Iguchi R, Ishitoya S, Sekine Y, Negoro H, Kurahashi R, Shimatani K, Saito R, Sawada A, Akamatsu S, Kobayashi T, Daimonji Clinical Application Database Group.

Eur J Surg Oncol. 2025 Jul 28;51(10):110357. doi: 10.1016/j.ejso.2025.110357. Online ahead of print. PMID: 40839311

 

Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort.

Saito R, Taoka R, Miki J, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Sazuka T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kinoshita H; Japan Urological Oncology Group.

Int J Clin Oncol. 2025 Jul 21. doi: 10.1007/s10147-025-02833-y. Online ahead of print. PMID: 40690100

 

Risk Stratification for the Prognosis of Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma.

Koterazawa S, Sumiyoshi T, Ito K, Masui K, Igarashi A, Inoue K, Ito N, Shibasaki N, Takuma T, Ueda M, Yamane T, Maekawa K, Kanamaru S, Hoshiyama A, Kanno T, Sugino Y, Hiramatsu K, Yoshida T, Koike S, Okubo K, Araki H, Masuda N, Nishizawa H, Yatsuda J, Saito R, Akamatsu S, Yamasaki T, Kamba T, Kobayashi T.

Clin Genitourin Cancer. 2025 Jul 11:102400. doi: 10.1016/j.clgc.2025.102400. Online ahead of print. PMID: 40744829

 

Aging potentially reduces CD169 expression in sinus macrophages of pelvic lymph nodes.

Ibe Y, Ozaki Y, Anami T, Yano H, Fujiwara Y, Nishizawa H, Kurahashi R, Motoshima T, Murakami Y, Yatsuda J, Komohara Y, Kamba T.

Med Mol Morphol. 2025 Mar 24. doi: 10.1007/s00795-025-00433-3. Online ahead of print. PMID: 40126633

 

Penile Cancer: Differences Between Patients Over and Under the Age of 75 Years.

Murakami Y, Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saitoh S, Kamba T.

Int J Urol. 2025;32(8):1025-1032.

 

Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective study.

Sazuka T, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Sawada A, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Ichikawa T; Japan Urological Oncology Group.

Int J Clin Oncol. 2025;30(7):1417-1425.

 

Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell Carcinoma.

Takahashi M, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Kawasaki Y, Kato T, Tatarano S, Masui K, Nakamura E, Kaneko T, Miyake M, Kitano G, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Kitamura H, Miyake H, Furukawa J; Japanese Urological Oncology Group.

Clin Genitourin Cancer. 2025;23(3):102322.

 

Reevaluating the therapeutic role of extended lymph node dissection in the era of robot-assisted radical prostatectomy.

Sawada A, Nishimoto K, Akamatsu S, Kubota M, Sumiyoshi T, Saito R, Kurahashi R, Sekine Y, Negoro H, Shiraishi Y, Iguchi R, Nakashima M, Kokura K, Iwamura H, Kohei N, Shimatani K, Kamoto T, Kobayashi T, Goto T; Daimonji Clinical Application Database (Dai-CAD) study group.

(Kamba T is also indicated in Acknowledgement.)

Sci Rep. 2025;15(1):17680.

 

Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low-Dose Estramustine in Very High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy.

Kambe T, Kubota M, Yamasaki T, Kawakita M, Murata S, Hattori Y, Tohi Y, Sekine Y, Kurahashi R, Shimatani K, Sawada A, Negoro H, Saito R, Goto T, Kobayashi T.

Prostate. 2025;85(7):684-692.

 

Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy.

Hatakeyama S, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga KI, Yamaguchi N, Taguchi M, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Ohyama C; Japan Urological Oncology Group.

Cancer Med. 2025;14(9):e70782.

 

Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.

Hara S, Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsubara Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kimura T; Japan Urological Oncology Group.

Int J Urol. 2025;32(5):544-552.

 

Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study.

Shiota M, Nemoto S, Ikegami R, Tanegashima T, Blas L, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Kobayashi K, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohayama C, Hashine K, Akamatsu S, Motoshima T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Eto M.

JCO Clin Cancer Inform. 2025;9:e2400167.

 

Enhancing thin slice 3D T2-weighted prostate MRI with super-resolution deep learning reconstruction: Impact on image quality and PI-RADS assessment.

Shiraishi K, Nakaura T, Kobayashi N, Uetani H, Nagayama Y, Kidoh M, Yatsuda J, Kurahashi R, Kamba T, Yamahita Y, Hirai T.

Magn Reson Imaging. 2025;117:110308.

 

Effects of aging on complications following robot-assisted radical prostatectomy.

Koterazawa S, Kubota M, Sumiyoshi T, Saito R, Takaoka N, Hattori Y, Shimizu Y, Kanno T, Soda T, Okada Y, Tsuchihashi K, Sekine Y, Negoro H, Kurahashi R, Shimatani K, Sawada A, Akamatsu S, Goto T, Kobayashi T.

Int J Clin Oncol. 2025;30(2):340-350.

 

The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study.

Shiota M, Tanegashima T, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Yokomizo A, Naito S, Eto M.

Prostate Cancer Prostatic Dis. 2025;28(1):193-201.

 

Impact of aspirin on biochemical recurrence of prostate cancer after robot assisted radical prostatectomy in a multicenter retrospective cohort study.

Suzuki S, Negoro H, Kubota M, Sumiyoshi T, Saito R, Okuno T, Segawa T, Fukuzawa S, Onishi H, Hattahara K, Nagahama K, Sekine Y, Kurahashi R, Shimatani K, Sawada A, Akamatsu S, Nishiyama H, Goto T, Kobayashi T.

Sci Rep. 2025;15(1):2025.

 

HIF1α Plays a Crucial Role in the Development of TFE3-Rearranged Renal Cell Carcinoma by Orchestrating a Metabolic Shift Toward Fatty Acid Synthesis.

Nishizawa H, Funasaki S, Ma W, Kubota Y, Watanabe K, Arima Y, Kuroda S, Ito T, Furuya M, Motoshima T, Nishiyama A, Mehanna S, Satou Y, Hasumi H, Jikuya R, Makiyama K, Tamura T, Oike Y, Tanaka Y, Suda T, Schmidt LS, Linehan WM, Baba M, Kamba T.

Genes Cells. 2025;30(1):e13195.

 

Immunohistochemical Analysis of a1-Acid Glycoprotein and Tumor Associated Macrophages in Clear Cell Renal Cell Carcinoma.

Ezaki A, Yano H, Pan C, Fujiwara Y, Anami T, Ibe Y, Ozaki Y, Nishizawa H, Motoshima T, Yatsuda J, Watanabe H, Maruyama T, Takeo T, Kamba T, Komohara Y.

Cancer Genomics Proteomics. 2025;22(1):103-111.

 

≪和文≫

後腹膜に発生した吻合血管腫の１例

髙橋えりか，倉橋竜磨，穴見俊樹，元島崇信，村上洋嗣，矢津田旬二，神波大己

西日泌尿. 2025;87(4):248-253.

 

人生100年時代のCABを再考する

倉橋竜磨

西日泌尿. 2025;87(4):207-208. (Proceedings)

 

腎癌ゲノム医療最前線　現状と将来展望

穴見俊樹，神波大己

西日泌尿. 2025;87(4):163-164. (Proceedings)